Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
CATX Stock Chart & Stats
$2.75
-$0.13(-3.36%)
At close: 4:00 PM EST
$2.75
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.60 - $5.39
Previous CloseN/A
Volume311.62K
Average Volume (3M)1.86M
Market Cap
$204.43M
Enterprise Value$231.39M
Total Cash (Recent Filing)$174.14M
Total Debt (Recent Filing)$3.31M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 26, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding74,337,990
10 Day Avg. Volume1,771,344
30 Day Avg. Volume1,857,362
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-2.83
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue275.13
Enterprise Value/Gross Profit-165.39
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$11.92Price Target Upside333.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$1.06M
Bulls Say, Bears Say
Bulls Say
Financial StabilityPerspective ended with ~$174M in cash, cash equivalents, and marketable securities, which provides a runway into late 2026.
Market ExpansionThe company is evaluating a potential expansion into other SSTR2 tumor types, such as breast and small cell lung cancer.
Safety ProfilePb-212-VMT-α-NET continues to be well tolerated with no Grade ≥ IV treatment-related adverse events or treatment-related discontinuations.
Bears Say
Competitive EfficacyVMT-α-NET's efficacy is lower than competitor SNY/OranoMed's 212Pb-DOTAMTATE.
Objective Response RateThe objective response rate (ORR) of 44% for VMT-α-NET falls below previous results and the higher bar set by competitor AlphaMedix, which reported a 60% ORR.
Stock PerformanceCATX stock is down ~26% following updated data for the VMT-a-NET program in NETs at the ESMO conference.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $1.60 and its highest was $5.39 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $204.43M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 95 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.321 by -$0.029.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 74,337,990 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.321. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.92 (333.45% Upside)
$11.92 (333.45% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 45.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $42.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.16%
12-Months-Change
Fundamentals
Return on Equity
-37.24%
Trailing 12-Months
Asset Growth
-24.63%
Trailing 12-Months
Company Description
Perspective Therapeutics
Perspective Therapeutics (CATX) is a biotechnology company focused on developing innovative therapeutic solutions within the healthcare sector. The company specializes in the research, development, and commercialization of cutting-edge treatments aimed at addressing complex medical conditions. Their core products and services include advanced therapeutics and technologies designed to improve patient outcomes and enhance the effectiveness of existing treatment regimens.
CATX Stock 12 Month Forecast
Average Price Target
$11.92
▲(333.45% Upside)
Technical Analysis
Ownership Overview
2.54% Insiders
17.46% Mutual Funds
11.49% Other Institutional Investors
60.03% Public Companies and Individual Investors